Genetic testing to guide treatment for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic myeloid leukemia (CML), confirmed by a special genetic test (BCR::ABL1 positive).
- You are at least 18 years old.
- You have not entered the advanced phase called blast crisis.
- You are currently taking imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), or bosutinib (Bosulif).
- Your doctor is planning to switch you to a different treatment because your current drug isn't working well enough (resistance) or because of a warning sign in your test results.
- You are NOT switching just because of side effects, and you have not had or are not planning a stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This study uses advanced DNA testing to look for inherited gene changes in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It may help explain whether your illness could be part of a family-linked risk syndrome, which can guide treatment and family planning.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.